Skip to main content

Multi-track investment for CordenPharma

CDMO CordenPharma is planning to invest heavily in all its platforms in terms of both capacities and capabilities, according to Dr Stephen Houldsworth, global head of platform management and marketing, who spoke with SCM at CPhI Worldwide in Milan.

In high potency, Houldsworth said, the firm has just signed off on an expansion of its development capabilities at Plankstadt in Germany. It is also expanding high potency capsule manufacture, where before Plankstadt was mostly focused on tablets, while adding hot melt extrusion to address bioavailability challenges.

Hovione to invest $170 million across three sites

CDMO Hovione used CPhI Worldwide 2021 in Milan to announce plans to invest $170 million over the years 2020-2022 to expand both capacities and capabilities at three sites in Portugal, Ireland, and New Jersey. About 300 jobs will be created as a result. These reflect its increasing focus on spray drying, high potency and particle engineering.

Flamma completes HPAPI suite

Flamma USA, the North American arm of the Italian CDMO, has completed the re-commissioning of the HPAPI suite at its site at Malvern, Pennsylvania, following an “exhaustive qualification” over the past six months. This is meant to be a viable alternative for customers early stage HPAPIs when lead times are long for others.

Major pipeline growth for Olon

At CPhI Worldwide 2021 in Milan on 9-11 November, Italian CDMO Olon announced “a significant expansion of its pipeline of APIs, a result of its R&D investment strategy”. In all, it has added nine new active substances for the generics market by investing across several lines and at multiple facilities in its network.

Meghmani Finechem into chlorotoluene

Indian chlor-alkali producer Meghmani Finechem is to spend €21.6 million to expand into the chlorotoluene value chain at its site in Dahej, Gujarat. Due to be commissioned by Q4 2024, this will be the first plant in India to be back-integrated into toluene chlorination, and will produce pharmaceutical and agrochemical intermediates.

CDMO expansion for AGC

AGC is to expand the production lines of its AGC Wakasa Chemicals subsidiary at the Kaminaka plant in Japan’s Fukui prefecture. The amount involved was not disclosed but the expansion, due to start operation in Q1 2024, will increase AGC Wakasa Chemicals’ manufacturing capacity by 50%, with more potentially to come.

New ADC technology from Merck KGaA

Merck KGaA’s Life Science business sector has launched ChetoSensar, a technology that improves the solubility of antibody-drug conjugates (ADCs). Over 20% of ADC candidates are terminated in clinical trials because of poor solubility. The company said that this supports it efforts to double its ADC and HPAPI capacity in the near future.

Subscribe to Pharmaceuticals